New Members Presenting in Rancho Mirage
_edited.jpg)
Pamela Bowie Morris, MD, FACC, FAHA, FASPC, FESC, FNLA
More Information Coming Soon!
%20-%20Lin%20Yee%20Chen_JPG.jpg)
Lin Yee Chen, MBBS, MS
Dr. Chen is a tenured Professor of Medicine, an ABIM board-certified cardiologist and cardiac electrophysiologist, and an NIH-funded physician-scientist. He is the Director of the Lillehei Heart Institute, a research institute in the University of Minnesota Medical School whose mission is to discover novel strategies to promote cardiovascular health and reduce suffering from cardiovascular disease. His patient-oriented research on atrial fibrillation and atrial myopathy is focused on 3 themes: (1) To identify novel risk factors for atrial fibrillation and atrial myopathy, and discover new strategies to prevent both conditions, (2) To characterize the relationship of atrial fibrillation and atrial myopathy to cardiovascular and neurocognitive outcomes such as stroke and dementia, and to elucidate the underlying mechanisms, and (3) To discover novel strategies to prevent atrial fibrillation and atrial myopathy-related stroke and dementia. As an Atherosclerosis Risk in Communities (ARIC), Multi-Ethnic Study of Atherosclerosis (MESA), and
Hispanic Community Health Study/Study of Latinos (HCHS/SOL) investigator, he conducts some of his research using data from these cohort studies. Currently, he is the PI of 5 NIH R01/RF1-funded projects, which are all focused on atrial fibrillation and atrial myopathy. In addition, he is the PI of a K24 grant, an NIH grant that expands his capacity in mentoring junior physician-scientists and scientists who are conducting patient-oriented research in cardiovascular science. Dr. Chen was elected to the American Society for Clinical Investigation in 2024.
Andrew Einstein, MD, PhD
Andrew Einstein works at Columbia University and New York-Presbyterian Hospital, where he serves as Director of Nuclear Cardiology, Cardiac CT, and Cardiac MRI, runs an advanced imaging fellowship for cardiologists, and is a tenured professor. Born and
raised in New Jersey, he received an A.B. from Princeton and attended Mount Sinai School of Medicine, where he received an M.D. as well as a Ph.D. in the Department of Biomathematical Sciences. His research in graduate school, which focused on developing image analysis methodology in histopathology and cytopathology, inculcated
a strong interest in medical imaging, but a passion for patient care refocused these interests to cardiology and cardiac imaging. He also received an M.S. in biostatistics/patient-oriented research from Columbia's Mailman School of Public Health. After internship and residency at Rutgers Robert Wood Johnson Medical School, he
completed fellowship training at Mount Sinai. Andrew’s clinical activities are centered on cardiovascular imaging using PET, SPECT, CT, and MRI, and inpatient cardiology. His research, which uses each of these modalities, focuses on improving the use of imaging in cardiovascular medicine, with particular interests and current funded projects in quality of healthcare, radiation safety, global health, amyloidosis, artificial intelligence, and drug and device development. It is funded by multiple NIH grants, the International Atomic Energy Agency, and industry, and has appeared in leading journals including NEJM, JAMA, Lancet, and Nature. Andrew has received ACC’s Douglas P. Zipes Distinguished Young Scientist Award and SNMMI's Hermann Blumgart Award, and is a
member of ASCI. He is the president-elect of ASNC, chair of ACC’s Young
Investigators Awards committee, and past chair of ACC’s Academic Cardiology section, a member of the editorial boards of JACC Imaging and the Journal of Nuclear Cardiology, and formerly served as an Associate Editor of JCCT. Andrew serves as a member of the Congressionally-chartered National Council on Radiation Protection and
Measurements and of the U.S. Nuclear Regulatory Commission's Advisory Committee on the Medical Uses of Isotopes, frequently represents the US at the International Atomic Energy Agency in Vienna, and was a member of FDA’s Medical Imaging Drugs Advisory Committee. He has served as a mentor to over fifty trainees at various stages
ranging from high school to junior faculty.
Jose Joglar, MD
Dr. Jose A. Joglar is Professor of Internal Medicine, Director of Cardiac Electrophysiology Fellowship Program and Vice Chair for Clinical Affairs at Parkland Health, Department of Internal Medicine, UT Southwestern Medical Center, in Dallas, Texas. Dr. Joglar is a board certified cardiac electrophysiologist with extensive clinical experience in arrhythmias in general. He has held many administrative leadership posts at his institution, has extensive experience in fellow’s education, and at the national levels belongs to numerous societies, national committees and editorial boards, including ECG section editor for Circulation and past chair of the Heart Rhythm Society Fellowship Programs Directors Committee. His academic career has centered on clinical practice guidelines developed and as such has been member of the writing committee in at least 7 different guidelines, including chair of the
writing committee for the 2023 Guideline for The Diagnosis and Management of Atrial Fibrillation. As Chief Medicine at Dallas County main safety net hospital and one of the most prominent public hospitals in the country, Parkland Memorial Hospital (Parkland Health), he
has extensive experience care of underserved communities as well as access to a diverse population of diverse racial and ethnic backgrounds.
.jpg)
Amit Khera, MD, MSc, FACC,
FAHA, MASPC
Dr. Khera is Professor of Medicine at the University of Texas, Southwestern Medical School in Dallas, Texas where he serves as Clinical Chief of Cardiology, Director of Preventive Cardiology, Co-Director of the Familial Hypercholesterolemia Clinic, and holder of the Dallas Heart Ball Chair in Hypertension and Heart Disease. He is also Professor of Epidemiology at the O’Donnell School of Public Health. He is Past
President of the American Society for Preventive Cardiology, Past President of the Dallas and SouthWest Region Boards of the AHA and past Chair of the AHA Scientific Sessions Planning Committee 2023 and 2024. He was named Master of the American Society for Preventive Cardiology in 2023. Dr. Khera is an Associate Editor for Circulation, and the American Journal of Preventive Cardiology which he helped to
found in 2020. He is an NIH funded investigator and has contributed over 250 publications in the field of preventive cardiology.
Mat Mauer, MD
Dr. Maurer is a general internist and geriatric cardiologist with advanced training in heart failure and cardiac transplantation. He is the Arnold and Arlene Goldstein Professor of Cardiology at Columbia University Irving Medical Center, Vagelos College of Physicians & Surgeons, where directs the Clinical Cardiovascular Research Laboratory for the Elderly (CCRLE) and the Cardiac Amyloidosis Program. He has published over 500 articles including peer reviewed manuscripts, reviews and book chapters. He was Chair of the American College of Cardiology’s Geriatric Cardiology Member Section, which is the largest organization dedicated to advancing the care of older adults with cardiovascular disease. He was co-chair of the Steering Committee of the ATTR-ACT trial showing tafamidis was a safe and effective therapy for transthyretin amyloid cardiomyopathy. Throughout his career, he has promulgated an approach to older adults with cardiovascular disease that offers the best of both geriatric and cardiovascular medicine in which a comprehensive holistic approach to enhance functional capacity and quality of life is at the forefront of emerging techniques to address cardiovascular physiologic derangement that disproportionately afflict older adults.
Sanjay Rajagopalan, MD, MBA,
FAHA, FACC
Dr. Sanjay Rajagopalan is the Chief of Cardiovascular Medicine, Chief Academic and Scientific Officer, University Hospitals Harrington Heart and Vascular Institute, Herman Hellerstein, MD Professor of Medicine and Biomedical Engineering and Director of the Case Cardiovascular
Research Institute at Case Western Reserve School of Medicine, Cleveland, OH. Dr. Rajagopalan is a graduate of the Sloan School of Management at MIT, specializing in health analytics and sustainability science. Dr. Rajagopalan is a well-known expert in the impact of
environmental pollution and climate change on cardiovascular health. He has led many innovative initiatives in healthcare centered around care delivery for high-risk patient populations, precision medicine imaging initiatives and next generation approaches for the prevention of heart and metabolic disease. Dr. Rajagopalan is an elected member of the
American Society of Clinical Investigation (ASCI), American Association of Physicians (AAP), Association of University Cardiologists and serves as President of the Association of Professors of Cardiology (APC). Dr. Rajagopalan is a recipient of the 2021 American College of
Cardiology’s (ACC) Distinguished Scientist Award (Translational Domain) as well as the 2025 American Heart Association (AHA) Distinguished Scientist Award.
%20-%20Mary%20Johns.jpg)
Marc Sabatine, MD, MHP
Marc S. Sabatine, MD, MPH is Chair of the Thrombolysis in Myocardial Infarction (TIMI) Study Group, the Lewis Dexter, MD, Endowed Chair in Cardiovascular Medicine at Brigham and Women’s Hospital (BWH), and a Professor of Medicine at Harvard Medical School (HMS). Dr. Sabatine graduated magna cum laude from Harvard College and received his medical degree magna cum laude from Harvard Medical School. He did his Internal Medicine residency, Chief Residency, and Cardiology clinical fellowship at the Massachusetts General Hospital (MGH). He received a Master of Public Health degree from the Harvard School of Public Health.
Dr. Sabatine attends in the cardiac intensive care units at both BWH & MGH. He is a Fellow of the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. He has been inducted into the American Society of Clinical Investigation. Dr. Sabatine is a member of the Faculty Council of HMS. As Chair of the TIMI Study Group, Dr. Sabatine leads an Academic Research Organization
whose mission over the past 40 years has been to advance the knowledge and care of patients suffering from cardiovascular disease and its risk factors. To that end, Dr. Sabatine has led multiple practice-changing, large-scale, international, randomized controlled trials of novel
antithrombotic, lipid-lowering, diabetes and other pharmacotherapies. A pioneer in the multimarker approach to risk stratification, Dr. Sabatine has had several NIH and American Heart Association grants supporting the application of proteomics and metabolomics for discovery of novel biomarkers. He has a long-standing interest in pharmacogenetics and has made seminal observations on the ability to use genetics for personalized medicine. Dr. Sabatine has authored over 500 papers, including in the New England Journal of Medicine, JAMA, and the Lancet. His work has been cited over 100,000 times, his h-index is >130, his i10-
index is 500, and he has been recognized as one of the most highly cited researchers (top ~0.1%) in medicine for many years running.
Dr. Sabatine has given Cardiology or Medical Grand Rounds at top academic centers around the world, has authored numerous review articles and book chapters, and is the editor of Pocket Medicine, now in its 9th edition, and Pocket Cardiology, now in its 3rd edition, the best-selling handbooks of internal medicine and cardiology. He has been on the writing committees for several U.S. and European practice guidelines. He is a Deputy Editor for JAMA Cardiology. Dr. Sabatine has taught at HMS for the past 2 decades. He also lectures internal medicine
residents at both BWH and MGH as part of their core curricula and takes Resident and Cardiology Fellow Report at both BWH and MGH. He has mentored over 2 dozen research fellows who have gone on to take academic cardiology positions nationally and internationally.